Harvard researchers have developed a method to monitor tissue repair within the brain using MRI and some nifty eye drops.
In this report, Harvard researchers describe how they link a relatively common MRI probe (superparamagnetic iron oxide nanoparticles) to a short DNA sequence that binds to proteins in cells responsible for brain tissue repair (glia and astrocytes). Then, researchers used the eye drops on mice with conditions that cause ‘leaks’ in the blood-brain barrier. When the animals’ brains were scanned using MRI, brain repair activity was visible. Glia and astrocytes help repair brain and nerve tissue, and have a role in numerous diseases and disorders that cause at least microscopic breaches in the blood-brain barrier, including traumatic brain injury, multiple sclerosis, stroke, cardiac arrest, and glioma, among others. Furthermore, the researchers believe that the probes may also help diagnose thinning of vascular walls in brains, which occurs as Alzheimer’s disease progresses.
“When people are sick, the last thing you want to do is puncture their skulls for a biopsy,” said Gerald Weissmann, MD, Editor-in-Chief of The FASEB Journal, “but sometimes this is unavoidable. These probes of genes in action go a long way toward ushering in an age where extracting brain tissue to identify a disease will seem as crude as when doctors measured skulls to diagnose a mental disease.”
Press release: Harvard researchers publish MRI images of genes in action in the living brain
System features, taken from the product brochure and product website:
The latest news from the ongoing meeting of the American College of Cardiology in Chicago is that using the Export® Aspiration Catheter from Medtronic before stenting, in patients with ongoing acute myocardial infarction (AMI), can “significantly improve blood flow and survival rates compared to conventional treatment with percutaneous coronary intervention (PCI) alone.” The study, led by Felix Zijlstra, MD, PhD from University Medical Center Groningen, Netherlands, recruited 1,071 patients who were randomly assigned to PCI supported by the Export aspiration catheter (535 pts) or to PCI using conventional techniques (536 pts).
Australian company SIRTeX has received FDA approval to begin trials of their injectable, beta radiating microspheres thought to directly target intrahepatic tumor sites.
A porous nanoparticle “capable of absorbing the energy of two photons in the near infrared spectrum, and then re-emitting radiation used for medical imaging by fluorescence” has been developed by an interdisciplinary group of scientists, reports Centre National de la Recherche Scientifique of France:
